Tiffany Y. Juan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tiffany Y. Juan has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Deng Pan
Tsinghua-Peking Center for Life Sciences, Department of Basic Medical Sciences, Tsinghua University, Beijing, China
103 shared publications - Jason W. Pyrdol
Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts
103 shared publications - John G. Doench
Genetic Perturbation Platform, Broad Institute, Cambridge, USA
103 shared publications - Kai W. Wucherpfennig
Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, USA
103 shared publications - Oleksandr Kyrysyuk
Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
103 shared publications - Wubing Zhang
Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts
103 shared publications
Latest Publications
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S7 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell–Secreted Cytokines
Supplementary Fig. S7 shows effect of PD-1 inhibition on treatment of tumors containing a B2m-/- population.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S7 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell–Secreted Cytokines
Supplementary Fig. S7 shows effect of PD-1 inhibition on treatment of tumors containing a B2m-/- population.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S8 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell–Secreted Cytokines
Supplementary Fig. S8 shows CD8 T cell-dependent control of tumors containing a B2m-/- population with inactivated Rnf31 and Atg5 genes.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S8 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell–Secreted Cytokines
Supplementary Fig. S8 shows CD8 T cell-dependent control of tumors containing a B2m-/- population with inactivated Rnf31 and Atg5 genes.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S3 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell–Secreted Cytokines
Supplementary Fig. S3 generation of tumor cell lines with multiple gene edits.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S3 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell–Secreted Cytokines
Supplementary Fig. S3 generation of tumor cell lines with multiple gene edits.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S5 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell–Secreted Cytokines
Supplementary Fig. S5 shows association of Atg5-KO and Rnf31/Atg5-dKO signatures with patient survival.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S5 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell–Secreted Cytokines
Supplementary Fig. S5 shows association of Atg5-KO and Rnf31/Atg5-dKO signatures with patient survival.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S10 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell–Secreted Cytokines
Supplementary Fig. S10 shows pharmacological sensitization to T cell cytokines in vitro and in vivo.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S10 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell–Secreted Cytokines
Supplementary Fig. S10 shows pharmacological sensitization to T cell cytokines in vitro and in vivo.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S6 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell–Secreted Cytokines
Supplementary Fig. S6 shows functional links between autophagy and cytokine signaling pathways.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S6 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell–Secreted Cytokines
Supplementary Fig. S6 shows functional links between autophagy and cytokine signaling pathways.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S11 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell–Secreted Cytokines
Supplementary Fig. S11 shows pharmacological sensitization of human melanoma cell line to T cell cytokines.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S11 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell–Secreted Cytokines
Supplementary Fig. S11 shows pharmacological sensitization of human melanoma cell line to T cell cytokines.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S4 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell–Secreted Cytokines
Supplementary Fig. S4 shows differentially expressed genes revealed by RNA-seq analysis.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S4 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell–Secreted Cytokines
Supplementary Fig. S4 shows differentially expressed genes revealed by RNA-seq analysis.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell–Secreted Cytokines
Supplementary Table S1: # Raw count of the genome-wide CRISPR screen for identifying T cell-mediated tumor killing in B2m-deficient cells. # MAGeCK results (Gene summary) for the genome-wide CRISPR screen from the B2m-deficient cells. # Gene log2FC in CRISPR screens from B2m-WT cells and B2m-KO cells. ## Common regulators of T cell mediated tumor killing in both B2m-WT and B2m-KO cells
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell–Secreted Cytokines
Supplementary Table S1: # Raw count of the genome-wide CRISPR screen for identifying T cell-mediated tumor killing in B2m-deficient cells. # MAGeCK results (Gene summary) for the genome-wide CRISPR screen from the B2m-deficient cells. # Gene log2FC in CRISPR screens from B2m-WT cells and B2m-KO cells. ## Common regulators of T cell mediated tumor killing in both B2m-WT and B2m-KO cells
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Table S3 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell–Secreted Cytokines
Supplementary Table S3: ## Raw count matrix of the RNA-seq data. ## Atg5-KO vs Ctrl-KO (Veh).
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell–Secreted Cytokines
Supplementary Table S3: ## Raw count matrix of the RNA-seq data. ## Atg5-KO vs Ctrl-KO (Veh).